Leyden Labs
leydenlabs.com
Actively hiring
Drug Discovery
Infectious Disease Therapeutics
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$167.2M
4 rounds on record
Latest round
$43.2M
Venture round · Jun 2026 · 4 mo ago
Hiring now
1
open roles
Backers
2
F-Prime Capital, GV
The money's age
Fresh money
4 months since the last round · hiring slowed
Momentum
35/100
in the news, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 26
Raised a round Venture round $43.2M · Pulse 2.0
Oct 2, 2025
Raised a round Venture round $32.4M · YahooFinance
Jun 3, 2025
Raised a round Venture round $21.6M
Jan 8, 2025
Raised a round Venture round $70M
2020
Founded
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jun 2026 | $43.2M | — | Pulse 2.0 |
| Venture round | Oct 2025 | $32.4M | — | YahooFinance |
| Venture round | Jun 2025 | $21.6M | — | leydenlabs.com |
| Venture round | Jan 2025 | $70M | — | businesswire.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Pulmocide, Draig Therapeutics
backs smartbax
Similar startupsby what they do, their industry and backers
Pulmocide is a biotechnology company developing novel inhaled medicines for pulmonary aspergillosis and other hard-to-treat respiratory…
At InvisiShield Technologies, we believe in preventing respiratory infections before they strike. Our mission is to create innovative…
Genvax Technologies is an animal vaccine company developing next-generation mRNA + nanoparticle vaccines from Ames, Iowa. Our mission is to…
Smartbax is dedicated to developing innovative antibiotics to combat the rising threat of multi-drug-resistant bacteria and protect global…
"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs".
Transforming the Future of Neuropsychiatry. Draig Therapeutics is developing transformative, best-in-class neuropsychiatric therapies to…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
F-Prime CapitalVia a fund
GVVia a fund
569 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Leyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma Patients
LEIDEN, The Netherlands, September 09, 2026--Leyden Laboratories B.V. (the "Company" or "Leyden Labs") today announced positive results from a Phase 1 study of RIG-101, an investigational intranasal innate immune modulator being developed to prevent the c
Read more
Report
Leyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma Patients
Leyden Labs reports positive Phase 1 results for RIG-101, an investigational intranasal therapy designed to strengthen antiviral defenses and help prevent virus-triggered asthma exacerbations. The results support RIG-101's advancement into Phase 2 clinica
Read more
Report
Leyden Labs Participated in HERA Implementation Dialogue on Preparing for Health Crises
The Leyden Labs team participated in HERA's recent Implementation Dialogue on July 3 in Brussels. In this dialogue, Commissioner Hadja Lahbib actively listened to a set of diverse stakeholders, who can each help prepare the EU for the next health crisis i
Read more
Report
Leyden Labs Raises €40 Million To Advance Respiratory Virus Protection Platform
Leyden Labs announced a €40 million investment to advance its mission of improving protection against influenza and other respiratory viruses.
Read more
Report
Globally Recognized Impact Investors Back Leyden Labs' Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment
Spanning Europe, the United States, and Asia, investors include the European Innovation Council (EIC) Fund, Invest-NL, Gates Foundation, ClavystBio, and others Ben Verwaayen appointed as a new Supervisory Board member LEIDEN, the Netherlands. June 25, 202
Read more
Report
Globally Recognized Impact Investors Back Leyden Labs' Mission to Transform Protection Against Respiratory Viruses with €40 Million Investment
Read more
Report
Leyden Labs Demonstrates Feasibility of Novel Antibody-Based Nasal Spray for Flu Prevention
The need for more effective protection against influenza continues to grow, as the virus consistently causes significant illness and mortality worldwide New human clinical data from Leyden Labs show intranasal delivery of broadly neutralizing antibodies c
Read more
Report
Leyden Labs Highlights Urgent Need to Accelerate Innovation in Nieuwsuur broadcast
On 13 December 2025, Leyden Labs appeared on Dutch national television in Nieuwsuur. During the broadcast, our CEO Koenraad Wiedhaup and TenneT CEO Manon van Beek discussed the crucial role of innovation in strengthening the Dutch economy and addressed th
Read more
Report
Leyden Labs: €30 Million Secured From EIC And Invest-NL
Dutch biotechnology company Leyden Laboratories B.V. has secured €30 million in new equity financing from the European Innovation Council (EIC) Fund and Invest-NL. The investment will accelerate the clinical development of the company's pan-influenza nasa
Read more
Report
Leyden Labs Secures €30 million from European Innovation Council Fund and Invest-NL to Advance Nasal Spray Against Respiratory Viruses
Dutch biotech Leyden Labs has raised a 30 million euro equity investment from the European Innovation Council (EIC) Fund and Invest-NL to accelerate the development of its PanFlu nasal spray. The support from the EIC Fund and Invest-NL helps strengthen Eu
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Leyden Labs over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
85/100
Cloud & platforms
Power BI
Sign in to see how your skills match this stack
Sign In
Growth
Hiring Momentum
44/100
Stable
Open positions
1
0 opened / 1 closed in 30 days
Median time-to-fill
51 days
faster than 26% of the market
ATS activity
Every ~6 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Finance
100% ▼
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Leiden
Leiden
Netherlands
HQ
2 open roles 1 posted in 90 days
hires for HR, Early Careers
Financials
Total raised
$167.2M
Latest round
Venture - Series Unknown
Funding rounds
4